BRAF and colorectal carcinoma: Activating mutations of BRAF (mostly V600E mutation), a serine/threonine kinase downstream of KRAS and upstream of MEK (mitogen-activated protein kinase kinase) have been reported to occur in approximately 10% of all CRC patients [67].